Skip to main
EMBC

Embecta Corp (EMBC) Stock Forecast & Price Target

Embecta Corp (EMBC) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Embecta is the global market leader in insulin administration products, producing ~8B units annually and distributing products in more than 100 countries. With a focus on generating cash, paying down debt, and returning cash to shareholders, the company's strong portfolio of marketed products and contract manufacturing services put it in a favorable position for long-term success in the diabetes care market. While recent commercial execution stumbles and declining profitability metrics raise some concerns, potential for growth in China and the company's new share buyback program suggest positive potential for investors.

Bears say

Embecta is facing commercial execution uncertainties and a disappointing profitability outlook, resulting in a downgrade from Buy to Neutral. While they have a broad portfolio of products and a strong global presence, the recent dividend cut and lower FCF generation expectations, along with lingering headwinds, have raised concerns about the company's financials. Additionally, the potential for competition, pricing pressure, and shifting market dynamics pose risks to the company's future performance.

Embecta Corp (EMBC) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Embecta Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Embecta Corp (EMBC) Forecast

Analysts have given Embecta Corp (EMBC) a Buy based on their latest research and market trends.

According to 2 analysts, Embecta Corp (EMBC) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Embecta Corp (EMBC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.